SP
SPRY.US ARS Pharmaceuticals, Inc
- Market cap
- USD 367M
- P/E
- -
- P/B
- 20.82x
- ROE
- -
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.
Is SPRY.US undervalued?
Graham numberThe Graham number of ARS Pharmaceuticals, Inc cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
ARS Pharmaceuticals, Inc fundamental analysis
No fundamental analysis for ARS Pharmaceuticals, Inc yet.
ARS Pharmaceuticals, Inc stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About ARS Pharmaceuticals, Inc
ARS Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes treatments for severe allergic reactions in the United States and internationally. The company is involved in the development of neffy, a needle-free intranasal delivery of epinephrine for emergency treatment of Type I allergic reactions, including anaphylaxis. ARS Pharmaceuticals, Inc. was founded in 2015 and is headquartered in San Diego, California.
Full company profileARS Pharmaceuticals, Inc financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
ARS Pharmaceuticals, Inc annual financial statements (USD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||
| Revenue | - | - | 17.8M | 5.51M | 1.32M | 30.0K | 89.1M | 84.3M | 125M |
| Gross Profit | -1.42M | -1.55M | 3.77M | 5.29M | -15.8M | 30.0K | 68.6M | 63.9M | 86.4M |
| Operating Income | -18.3M | -24.1M | -469K | -19.5M | -35.5M | -67.5M | -3.08M | -179M | -208M |
| EBITDA | -16.9M | -22.5M | -463K | -19.9M | -34.4M | -54.3M | 8.37M | -167M | -200M |
| Net Income | -17.6M | -24.0M | -1.07M | -20.2M | -34.7M | -54.4M | 8.00M | -171M | -211M |
| EPS | -0.53 | -0.72 | -0.03 | -0.70 | -0.87 | -0.57 | 0.08 | -1.74 | -2.12 |
| Balance Sheet | |||||||||
| Total Assets | 27.5M | 15.6M | 26.4M | 61.4M | 281M | 233M | 351M | 328M | 251M |
| Total Liabilities | 9.35M | 21.3M | 40.5M | 92.7M | 8.55M | 2.43M | 94.4M | 213M | 263M |
| Shareholders' Equity | 18.2M | -5.60M | -14.1M | -31.3M | 273M | 231M | 257M | 114M | -12.0M |
| Cash & Short-term Investments | 20.2M | 9.98M | 24.5M | 60.1M | 274M | 228M | 314M | 245M | 138M |
| Total Debt | 7.73M | 15.6M | 10.0M | 9.03M | 481K | 274K | 42.0K | 96.4M | 197M |
| Cash Flow | |||||||||
| Operating Cash Flow | -16.9M | -18.9M | 9.07M | -17.6M | -40.1M | -59.3M | 13.5M | -171M | -186M |
| Capital Expenditure | 449K | 96.0K | 917K | 55.0K | 199K | 175K | 563K | 339K | 0.00 |
| Free Cash Flow | -17.3M | -19.0M | 8.15M | -17.6M | -40.3M | -59.4M | 13.0M | -171M | -186M |
| Ratios | |||||||||
| ROE | -96.6% | - | - | - | -12.7% | -23.6% | 3.1% | -149.9% | - |
| ROA | -63.8% | -153.2% | -4.0% | -32.9% | -12.3% | -23.3% | 2.3% | -52.3% | -84.1% |
| Net Profit Margin | - | - | -6.0% | -367.7% | -2,635.4% | -181,216.7% | 9.0% | -203.3% | -168.6% |
| Debt to Equity | 0.43x | - | - | - | 0.00x | 0.00x | 0.00x | 0.84x | - |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
ARS Pharmaceuticals, Inc dividends
ARS Pharmaceuticals, Inc has not paid dividends in the last 8 fiscal years.
Who owns ARS Pharmaceuticals, Inc
- Insiders 16.01%
- Institutions 83.99%
- Public & others 0.00%
- Shares outstanding 101M
- Free float 49.1M
Top funds holding SPRY.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| State Street® SPDR® S&P® Biotech ETF | 2.33M | 2.33% | +2.69% | Oct 2026 |
| American Funds SMALLCAP World A | 1.91M | 1.90% | -28.83% | Sep 2026 |
| Vanguard MStar Total Stk Mkt Idx Invest | 1.75M | 1.75% | 0.00% | Sep 2026 |
| abrdn Healthcare Opportunities | 1.70M | 1.70% | +53.50% | Sep 2026 |
| iShares Russell 2000 ETF | 1.57M | 1.57% | 0.00% | Oct 2026 |
| abrdn Healthcare Investors | 1.50M | 1.50% | 0.00% | Oct 2026 |
| Fidelity Small Cap Index | 709K | 0.71% | +5.70% | Aug 2026 |
| iShares Russell 2000 Growth ETF | 585K | 0.58% | -0.38% | Oct 2026 |
| iShares Biotechnology ETF | 488K | 0.49% | -0.19% | Oct 2026 |
| UBS (Lux) EF Biotech (USD) P-acc | 410K | 0.41% | 0.00% | Jul 2026 |
| Fidelity Global Healthcare A-Dis-EUR | 407K | 0.41% | -0.34% | Sep 2026 |
| Vanguard Russell 2000 ETF | 359K | 0.36% | +1.29% | Sep 2026 |
| Schwab US Small-Cap ETF™ | 338K | 0.34% | +0.24% | Oct 2026 |
| Fidelity Select Biotechnology | 335K | 0.33% | 0.00% | Aug 2026 |
| Empire Life American Value Cl A | 313K | 0.31% | 0.00% | Sep 2026 |
| Fidelity Extended Market Index | 307K | 0.31% | -9.65% | Sep 2026 |
| A4Investments SICAV SIF ACCI IlanaA2EURH | 180K | 0.18% | +5.88% | Oct 2026 |
| Vanguard Health Care ETF | 144K | 0.14% | +0.11% | Sep 2026 |
| Schwab Small Cap Index | 141K | 0.14% | -5.92% | Sep 2026 |
| Fidelity Total Market Index | 124K | 0.12% | -0.05% | Sep 2026 |
Top institutions holding SPRY.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| RA Capital Management, LLC | 10.9M | 10.83% | 0.00% | Jun 2026 |
| Rubric Capital Management LP | 8.54M | 8.52% | +6.76% | Jun 2026 |
| Orbimed Advisors LLC | 8.29M | 8.27% | 0.00% | Jun 2026 |
| Deerfield Management Co | 7.50M | 7.49% | 0.00% | Jun 2026 |
| BlackRock Inc | 5.31M | 5.30% | +5.97% | Jun 2026 |
| Tyro Capital Management LLC | 4.46M | 4.45% | +50.22% | Jun 2026 |
| SR ONE CAPITAL MANAGEMENT, LP | 4.01M | 4.00% | 0.00% | Jun 2026 |
| State Street Corp | 3.73M | 3.72% | +2.35% | Jun 2026 |
| Capital World Investors | 2.75M | 2.75% | 0.00% | Jun 2026 |
| Vanguard Capital Management, LLC | 2.55M | 2.55% | +0.43% | Jun 2026 |
| Millennium Management LLC | 2.40M | 2.40% | -59.87% | Jun 2026 |
| Janney Montgomery Scott LLC | 2.06M | 2.06% | +2.38% | Jun 2026 |
| UBS Group AG | 1.94M | 1.93% | -14.19% | Jun 2026 |
| Aberdeen Group PLC | 1.70M | 1.70% | -59.22% | Sep 2026 |
| Geode Capital Management, LLC | 1.70M | 1.69% | +11.28% | Jun 2026 |
| BOOTHBAY FUND MANAGEMENT, LLC | 1.60M | 1.60% | +539.08% | Jun 2026 |
| Third Point, LLC | 1.00M | 1.00% | 0.00% | Jun 2026 |
| General American Investors Co Inc | 908K | 0.91% | -19.82% | Sep 2026 |
| Pavaki Capital Management LLC | 660K | 0.66% | +13.80% | Sep 2026 |
| ADAR1 Capital Management LLC | 601K | 0.60% | -55.86% | Jun 2026 |
ARS Pharmaceuticals, Inc company profile
- Company name
- ARS Pharmaceuticals, Inc
- Ticker
- SPRY.US
- Exchange
- USA Stocks
- Listed since
- Dec 4, 2020
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 203
- Fiscal year end
- December
- Address
- 11682 El Camino Real, San Diego, CA, United States, 92130
- Phone
- 858 771 9307
- Website
- ars-pharma.com
About ARS Pharmaceuticals, Inc
ARS Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes treatments for severe allergic reactions in the United States and internationally. The company is involved in the development of neffy, a needle-free intranasal delivery of epinephrine for emergency treatment of Type I allergic reactions, including anaphylaxis. ARS Pharmaceuticals, Inc. was founded in 2015 and is headquartered in San Diego, California.
ARS Pharmaceuticals, Inc management
9- Mr. Justin ChakmaChief Business Officer · born 1990
- Mr. Donn CasaleCEO, President & Director · born 1973
- Dr. Robert Bell Ph.D.Co-Founder & Chief Science Officer
- Ms. Kathleen D. Scott CPAChief Financial Officer
- Mr. Brian T. Dorsey M.S.Chief Operating Officer · born 1969
- Mr. Alexander A. Fitzpatrick Esq.Chief Legal Officer & Secretary · born 1967
- Mr. Daniel RelovskySenior Vice President of Marketing
- Ms. Lynda HarrisVice President of Human Resources
- Mr. Eric KarasChief Commercial Officer · born 1973